文献速递妇科

系统性免疫炎症指数可预测上皮性卵巢癌患者预后:一项回顾性研究

Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
PubMed 文献 · Gynecol Oncol · 2018-12-14

该回顾性研究纳入553例上皮性卵巢癌患者,发现队列250例来自四川大学华西第二医院,验证队列283例来自西南医科大学附属医院。高SII(≥612)与晚期FIGO分期、淋巴结转移和肿瘤复发相关;在多因素Cox回归中,SII是发现队列无进展生存期(HR=7.61,95%CI 3.34-17.35,P<0.001)和总生存期(HR=6.36,95%CI 2.64-15.33,P<0.001)的独立预后指标,并在验证队列中得到验证。

要点

  • 高SII(≥612)与晚期FIGO分期、淋巴结转移和肿瘤复发相关。
  • 发现队列中高SII(≥612)患者PFS和OS较低SII(<612)患者显著缩短。
  • 多因素Cox回归显示SII是EOC患者PFS和OS的独立预后因素。

核心结论

  • 高SII与上皮性卵巢癌患者生存不良相关。
  • SII是上皮性卵巢癌患者的独立预后因素。

研究设计与样本

  • 回顾性研究,共分析553例上皮性卵巢癌患者。
  • 发现队列为来自四川大学华西第二医院的250例患者,验证队列为来自西南医科大学附属医院的283例患者。
  • 采用Cox回归分析和Kaplan-Meier法分析SII与生存的相关性,用受试者工作特征(ROC)曲线评估预测准确性。

主要发现

  • 高SII(≥612)与晚期FIGO分期、淋巴结转移和肿瘤复发相关。
  • 单因素Cox回归中,两个队列的高SII(≥612)患者较低SII(<612)患者PFS和OS均显著缩短。
  • 多因素Cox回归分析中,发现队列SII是PFS的独立预后指标(HR=7.61,95%CI 3.34-17.35,P<0.001)。
  • 多因素Cox回归分析中,发现队列SII是OS的独立预后指标(HR=6.36,95%CI 2.64-15.33,P<0.001)。
  • 上述结果在验证队列中得到验证。

关键数值与推荐

  • 高SII定义为≥612,低SII定义为<612。
  • 发现队列PFS的HR=7.61(95%CI 3.34-17.35,P<0.001)。
  • 发现队列OS的HR=6.36(95%CI 2.64-15.33,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aimed to investigate the prognostic value of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC). METHODS: A total of 553 EOC patients were retrospectively analyzed. 250 patients from West China Second University Hospital were assigned into the discovery cohort and 283 patients from The Affiliated Hospital of Southwest Medical University were assigned into the validation cohort. The correlation between SII and survival were analyzed using Cox regression analyses and Kaplan-Meier method. Prediction accuracy was evaluated with the receiver operating characteristics (ROC) curve. RESULTS: The high SII (≥612) was correlated with advanced FIGO stage, lymph node metastasis, and tumor recurrence. In univariate Cox regression, patients with high SII (≥612) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to low SII patients (<612) in both cohorts. In multivariate Cox regression analysis, SII was an independent prognostic indicator for PFS (HR = 7.61, 95% CI 3.34-17.35, P < 0.001) and OS (HR = 6.36, 95% CI 2.64-15.33, P < 0.001) in the discovery cohort. These results were verified in the validation cohort. CONCLUSION: High SII was correlated with poor survival in patients with EOC. The SII was an independent prognostic factor for patients with EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nie D, Gong H, Mao X, et al. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study. Gynecol Oncol. 2018. PMID: 30558974. doi:10.1016/j.ygyno.2018.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。